Regional and insurance-based differences in biologic initiation for psoriasis among Medicare and commercially insured individuals in the United States: A Merative Marketscan analysis - 18/12/25
Doi : 10.1016/j.jaad.2025.09.049
Qiwei Wilton Sun, BA a, Jeffrey M. Cohen, MD, MPH a, b, ⁎ 
a Department of Dermatology, Yale School of Medicine, New Haven, Connecticut
b Department of Biomedical Informatics and Data Science, Yale School of Medicine, New Haven, Connecticut
∗ Correspondence to: Jeffrey M. Cohen, MD, MPH, Department of Dermatology and Department of Biomedical Informatics and Data Science, 15 York St, New Haven, CT 06510 Department of Dermatology and Department of Biomedical Informatics and Data Science 15 York St New Haven CT 06510
Key words : biologics, geographic variation, insurance coverage, metropolitan, psoriasis
| Funding sources: This work was supported in part by the Yale School of Medicine Office of Student Research. |
|
| Patient consent: Not applicable. |
|
| IRB approval status: This study was not considered to be human subject research by the Yale University Institutional Review Board and thus IRB approval was not necessary. |
© 2025
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 94 - N° 1
P. 345-347 - janvier 2026 Retour au numéro
Article précédent
- Upper hair follicle transplantation combined with 308 nm excimer laser for refractory vitiligo: A promising therapeutic approach
- Yi Wu, Mengying Duan, Yeqin Dai, Xiuzu Song
- Efficacy of Phototherapy in Managing Cutaneous Immune-Related Adverse Events in Patients Treated With Checkpoint Inhibitors
- Sukul Mittal, Elissa Goorman, Jennifer N. Choi, Cuong V. Nguyen
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?